SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-046016
Filing Date
2023-09-29
Accepted
2023-09-29 16:38:18
Documents
12
Period of Report
2023-09-29
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K ef20011657_8k.htm   iXBRL 8-K 27058
  Complete submission text file 0001140361-23-046016.txt   166130

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atai-20230929.xsd EX-101.SCH 3856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20230929_lab.xml EX-101.LAB 23290
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20230929_pre.xml EX-101.PRE 16546
6 EXTRACTED XBRL INSTANCE DOCUMENT ef20011657_8k_htm.xml XML 4213
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 231296276
SIC: 2834 Pharmaceutical Preparations